UAMS Receives Funds from GlaxoSmithKline for Research on Drug Abuse Treatment

By todd

The GlaxoSmithKline Graduate Fellowship in Pharmacokinetics will support a graduate student in the laboratory of S. Michael Owens, Ph.D., the Wilbur D. Mills Chair in Alcoholism and Drug Abuse Prevention in the Department of Pharmacology and Toxicology of the UAMS College of Medicine.

“We appreciate the support of GlaxoSmithKline. Corporate gifts for research help us prepare a new generation of scientists who will be able to contribute to better public health as well as economic development. This gift from GlaxoSmithKline is a wonderful example of how corporate philanthropy supports higher education and academic health centers,” Owens said.

“The GlaxoSmithKline Graduate Fellowship in Pharmacokinetics is designed to provide funding for graduate level scientists in their pursuit of knowledge in preclinical pharmacokinetics,” said Henk Solleveld, GSK vice president for preclinical drug discovery. “We hope this fellowship will function as a stimulus for graduates to enter this challenging field of applied research.”

About GlaxoSmithKline

GlaxoSmithKline scientists and other employees around the world are searching for new and better treatments for a variety of diseases. In 2002, the company spent approximately $4.1 billion in research and development. The company has been widely recognized for its therapeutic areas of research that include respiratory, anti-viral – including HIV – therapies, anti-infectives, central nervous system, cardiovascular, oncology, anesthesia, and metabolic diseases such as diabetes.